利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.02 秒)

    DNA vaccines against tumor growth and methods of use thereof
    12.
    发明授权
    DNA vaccines against tumor growth and methods of use thereof 有权
    针对肿瘤生长的DNA疫苗及其使用方法

    公开(公告)号：US08716254B2

    公开(公告)日：2014-05-06

    申请号：US10807897

    申请日：2004-03-24

    申请人： Rong Xiang ,  He Zhou ,  Ralph A. Reisfeld

    发明人： Rong Xiang ,  He Zhou ,  Ralph A. Reisfeld

    IPC分类号： A61K39/00 ,  A61K6/00

    CPC分类号： A61J1/05 ,  A61K6/00 ,  A61K39/0011 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55522 ,  Y02A50/484

    摘要： A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA, human MICB, human ULBP1, human ULBP2, and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the invention to a mammal is also described.

    摘要翻译： 适用于引发针对癌细胞的免疫应答的DNA疫苗包括可操作地编码癌相关的凋亡家族蛋白抑制剂的DNA构建体和免疫活性基因产物，例如细胞因子或天然杀伤细胞表面受体的配体， 药学上可接受的载体。 优选的细胞因子是CCL21。 用于天然杀伤细胞表面受体的优选配体包括人MICA，人MICB，人ULBP1，人ULBP2和人ULBP3。 癌症相关的凋亡抑制剂（IAP）家族蛋白质优选是存活蛋白质蛋白质或livin蛋白质。 还描述了通过将哺乳动物施用本发明的疫苗来抑制肿瘤生长的方法。

    DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
    14.
    发明授权
    DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof 失效
    编码CEA和CD40配体的DNA疫苗及其使用方法

    公开(公告)号：US07279464B2

    公开(公告)日：2007-10-09

    申请号：US11195506

    申请日：2005-08-02

    申请人： Rong Xiang ,  Ralph A. Reisfeld

    发明人： Rong Xiang ,  Ralph A. Reisfeld

    IPC分类号： A61K35/00 ,  A61K38/43 ,  A61K48/00 ,  C12N15/63 ,  C12N15/00

    CPC分类号： A61K39/0011 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/55533 ,  C07K14/70503 ,  C07K14/70575

    摘要： A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.

    摘要翻译： 有效地引发针对呈现癌胚抗原（CEA）的细胞的免疫应答的DNA疫苗分别包含可操作地编码CEA的DNA和可操作地编码CD40配体SEQ ID NO：1和SEQ ID NO：2的DNA，或 其同源三聚体，CD40LT。 DNA疫苗可以并入递送载体如减毒活细菌或病毒或脂质体载体中。 在方法实施方案中，将DNA疫苗口服给予哺乳动物（例如人）以引发针对CEA呈递细胞例如结肠癌细胞的免疫应答。 优选的方法实施方案包括用重组抗体融合蛋白huKS1 / 4-IL2处理哺乳动物以增强疫苗的免疫应答有效性的附加步骤。

    EX vivo effector cell activation for target cell killing
    18.
    发明授权
    EX vivo effector cell activation for target cell killing 失效
    用于靶细胞杀伤的体外效应细胞活化

    公开(公告)号：US4844893A

    公开(公告)日：1989-07-04

    申请号：US916173

    申请日：1986-10-07

    申请人： Cyril J. Honsik ,  Ralph A. Reisfeld

    发明人： Cyril J. Honsik ,  Ralph A. Reisfeld

    IPC分类号： C12N5/06 ,  A61K35/14 ,  A61K45/00 ,  A61K47/48 ,  C12N5/02

    CPC分类号： A61K47/48369 ,  Y10S424/804 ,  Y10S530/808 ,  Y10S530/828

    摘要： A method and composition for killing target cells is disclosed. The method utilizes ex vivo IL-2 activation of leucocyte effector cells and arming the activated leucocyte effectors with monoclonal antibodies whose Fc portions bind to the IL-2-activated effectors and whose paratopic portions immunoreact with an epitope expressed on the surfaces of the target cells. The composition contains a cytolytic amount of the armed, IL-2-activated effector cells dispersed in an aqueous physiologically tolerable diluent medium.

    摘要翻译： 公开了一种杀死靶细胞的方法和组合物。 该方法利用白细胞效应细胞的离体IL-2激活和用Fc部分结合IL-2活化的效应物并且其互补部分与靶细胞表面上表达的表位免疫反应的单克隆抗体来装备活化的白细胞效应子 。 组合物含有分散在水性生理上可耐受的稀释培养基中的溶解量的经驱动的IL-2活化的效应细胞。